Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Summary

The goal of this clinical research study is to find out if Revlimid can help to control the disease in patients with relapsed/refractory acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS) with abnormalities in chromosome number 5. The safety of this treatment will also be studied.

Timeline

Start

2009-01

Primary completion

2012-05

Completion

2012-05

Drugs

Indications